EPO and myelodysplastic syndrome: As one of the hallmarks of SF3B1‐mutated MDS is anemia caused by marked ineffective maturation of erythroblasts in the bone marrow, this commonly results in a higher endogenous EPO level, rendering patients with SF3B1 mutation less responsive to ESA.91, 92